Hybrid Media: Examines Pancreatic Cancer and Oil Spills Two Years After The BP Disaster

Robert Graham Reporting From OTC Offshore Technology Conference Houston, Texas April 30, 2012 A Interview with Rose Conrad GenNXeix Biotech Inc C.E.O

---

Hybrid Media: Examines Pancreatic Cancer and Oil Spills Two Years After The BP Disaster

---

All Workers Exposed To The BP Disaster should get a Genomics Test for Pancreatic Cancer says Rose Conrad Ph.D. Gennxeix Biotech researchers can compare normal and tumor DNA has shown that the gene for a subunit of the multi-subunit SWI/SNF protein complex was either deleted, mutated or rearranged in about a third of the 70 human pancreatic cancers from the region

that the GenNXeix team examined. Gennxeix researchers found that restoring the expression of one of the missing genes slowed the growth of pancreatic cancer cells. The pancreatic cancer enter a state called senescence. "This is really strong genetic evidence that this complex plays a role in pancreatic cancer, and it suggests the influence of the SWI/SNF complex is on par with that of other well-known tumor suppressors, such as p53. The tumor-suppressing role of the SWI/SNF complex We should not that, one person's pancreatic cancer might have a mutation or deletion in one protein subunit, while another's could have a change in a different subunit. Gennxeix used a array comparative genomic hybridization, or CGH, to pinpoint places in the genome that differed among normal and

cancerous pancreatic epithelial cells. The procedure relies on the ability of single-stranded DNA to seek out and bind to its mirror image. By comparing the relative amounts of tumor and normal DNA that bind to a panel of reference sequences, the researchers can tell whether the cancer cell contains amplifications or deletions of genetic material in specific regions throughout the genome. These copy-number variations often occur in genes or regions important in regulating uncontrolled cell growth. The researchers examined about 35 different pancreatic cancers, . 24 of the cancers were primary samples from human patients that had been asked to grow in immune-deficient mice; 11 had been maintained as laboratory-grown cancer cell lines. Gennxeix used high-density arrays of reference DNA sequences for the CGH, which allowed the identifi mplified or deleted regions at a much higher resolution than previously possible -- narrowing the areas of interest to just a few

thousand nucleotides rather than larger stretches of DNA. GeNnxeix looked at the results of the array CGH analysis, and observed that genes known to be involved in pancreatic cancer, and also some new candidates. In particular, they noticed that the genes for individual subunits of the SWI/SNF complex were altered in about 5 to 10 percent of the cancer samples -- an interesting finding, but not prevalent enough to spark further immediate investigation under normal circumstances. realized that more than a third of the cancer samples contained a deletion, mutation or rearrangement in the genes.